Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels.
Soins de soutienHydratation
#5
Y a-t-il des traitements spécifiques pour les effets chroniques ?
Les traitements des effets chroniques incluent la réhabilitation et le suivi médical.
RéhabilitationSuivi médical
Complications
5
#1
Quelles complications peuvent survenir après exposition ?
Des complications incluent des troubles hépatiques, rénaux et neurologiques.
ComplicationsTroubles hépatiques
#2
Y a-t-il des risques de cancer associés ?
Une exposition prolongée peut augmenter le risque de certains cancers.
CancerExposition prolongée
#3
Comment les complications sont-elles surveillées ?
Des examens médicaux réguliers et des tests de fonction organique sont nécessaires.
Surveillance médicaleTests de fonction
#4
Les complications peuvent-elles être réversibles ?
Certaines complications peuvent être réversibles avec un traitement précoce.
Complications réversiblesTraitement précoce
#5
Quels sont les effets à long terme possibles ?
Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels.
Effets à long termeTroubles chroniques
Facteurs de risque
5
#1
Qui est le plus à risque d'exposition ?
Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque.
TravailleursIndustrie chimique
#2
Quels environnements augmentent le risque ?
Les environnements de travail mal ventilés et non sécurisés augmentent le risque.
Environnements de travailVentilation
#3
Y a-t-il des facteurs génétiques impliqués ?
Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité.
Facteurs génétiquesSusceptibilité
#4
Comment l'âge influence-t-il le risque ?
Les personnes âgées peuvent être plus vulnérables aux effets toxiques.
ÂgeVulnérabilité
#5
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque.
Antécédents médicauxMaladies hépatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "1,1',1''-Phosphoryltriaziridine : Questions médicales les plus fréquentes",
"headline": "1,1',1''-Phosphoryltriaziridine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 1,1',1''-Phosphoryltriaziridine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-09",
"dateModified": "2025-04-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aziridines",
"url": "https://questionsmedicales.fr/mesh/D001388",
"about": {
"@type": "MedicalCondition",
"name": "Aziridines",
"code": {
"@type": "MedicalCode",
"code": "D001388",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Thiotépa",
"alternateName": "Thiotepa",
"url": "https://questionsmedicales.fr/mesh/D013852",
"about": {
"@type": "MedicalCondition",
"name": "Thiotépa",
"code": {
"@type": "MedicalCode",
"code": "D013852",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217.935.960"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine",
"alternateName": "Triethylenephosphoramide",
"code": {
"@type": "MedicalCode",
"code": "D013721",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liusheng Huang",
"url": "https://questionsmedicales.fr/author/Liusheng%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Beth Apsel Winger",
"url": "https://questionsmedicales.fr/author/Beth%20Apsel%20Winger",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of California San Francisco."
}
},
{
"@type": "Person",
"name": "Vincent Cheah",
"url": "https://questionsmedicales.fr/author/Vincent%20Cheah",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "David Gingrich",
"url": "https://questionsmedicales.fr/author/David%20Gingrich",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Florence Marzan",
"url": "https://questionsmedicales.fr/author/Florence%20Marzan",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Hearing Outcomes of a New Cartilage Conduction Device vs Bone Conduction Devices.",
"datePublished": "2023-01-29",
"url": "https://questionsmedicales.fr/article/36066979",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/01945998221123057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Speech in Noise With Bilateral Active Bone Conduction Implant for Conductive and Mixed Hearing Loss.",
"datePublished": "2022-08-30",
"url": "https://questionsmedicales.fr/article/36040056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MAO.0000000000003671"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intracochlear pressure and temporal bone motion interaction under bone conduction stimulation.",
"datePublished": "2023-05-26",
"url": "https://questionsmedicales.fr/article/37267833",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.heares.2023.108818"
}
},
{
"@type": "ScholarlyArticle",
"name": "A bone conduction implant using self-drilling screws : Self-drilling screws as a new fixation method of an active transcutaneous bone conduction hearing implant.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37322168",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00106-023-01295-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Results of a Novel, Nonsurgical Bone-Conduction Hearing Aid for the Treatment of Conductive Hearing Loss in Australian Children.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37621119",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MAO.0000000000003995"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Azirines",
"item": "https://questionsmedicales.fr/mesh/D001389"
},
{
"@type": "ListItem",
"position": 5,
"name": "Aziridines",
"item": "https://questionsmedicales.fr/mesh/D001388"
},
{
"@type": "ListItem",
"position": 6,
"name": "1,1',1''-Phosphoryltriaziridine",
"item": "https://questionsmedicales.fr/mesh/D013721"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 1,1',1''-Phosphoryltriaziridine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?\nQuels tests sont utilisés pour évaluer la toxicité ?\nQuels symptômes indiquent une intoxication ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment évaluer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Conduction#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quels sont les symptômes d'une exposition aiguë ?\nPeut-on avoir des symptômes neurologiques ?\nQuels symptômes digestifs peuvent apparaître ?\nY a-t-il des symptômes cutanés associés ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Conduction#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment prévenir l'exposition au Triethylenephosphoramide ?\nQuelles formations sont nécessaires pour les travailleurs ?\nQuels sont les protocoles de sécurité recommandés ?\nComment gérer les déchets contenant ce composé ?\nY a-t-il des recommandations pour les laboratoires ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Conduction#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quel est le traitement principal en cas d'intoxication ?\nDes antidotes existent-ils pour ce composé ?\nComment traiter les symptômes neurologiques ?\nQuelles mesures de soutien sont recommandées ?\nY a-t-il des traitements spécifiques pour les effets chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Conduction#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quelles complications peuvent survenir après exposition ?\nY a-t-il des risques de cancer associés ?\nComment les complications sont-elles surveillées ?\nLes complications peuvent-elles être réversibles ?\nQuels sont les effets à long terme possibles ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Conduction#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 1,1',1''-Phosphoryltriaziridine",
"description": "Qui est le plus à risque d'exposition ?\nQuels environnements augmentent le risque ?\nY a-t-il des facteurs génétiques impliqués ?\nComment l'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Conduction#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests biologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la toxicité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses d'urine peuvent détecter des métabolites toxiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme les enzymes hépatiques peuvent indiquer une toxicité."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets à long terme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des évaluations cliniques sont nécessaires pour détecter des effets chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent des maux de tête, des vertiges et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques comme des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes digestifs peuvent apparaître ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées, vomissements et diarrhées sont fréquents après exposition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des irritations peuvent se manifester après contact."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si l'exposition se poursuit."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au Triethylenephosphoramide ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles formations sont nécessaires pour les travailleurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations sur la manipulation sécurisée des produits chimiques sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de sécurité recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles incluent des procédures d'urgence et des contrôles d'exposition réguliers."
}
},
{
"@type": "Question",
"name": "Comment gérer les déchets contenant ce composé ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déchets doivent être éliminés selon les réglementations en vigueur pour les produits toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les laboratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les laboratoires doivent avoir des systèmes de ventilation et des douches de sécurité."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'élimination de l'exposition et le soutien symptomatique."
}
},
{
"@type": "Question",
"name": "Des antidotes existent-ils pour ce composé ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Comment traiter les symptômes neurologiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes neurologiques peuvent nécessiter des médicaments anticonvulsivants."
}
},
{
"@type": "Question",
"name": "Quelles mesures de soutien sont recommandées ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les effets chroniques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements des effets chroniques incluent la réhabilitation et le suivi médical."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après exposition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles hépatiques, rénaux et neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles surveillées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens médicaux réguliers et des tests de fonction organique sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque."
}
},
{
"@type": "Question",
"name": "Quels environnements augmentent le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les environnements de travail mal ventilés et non sécurisés augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent être plus vulnérables aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque."
}
}
]
}
]
}
To compare audiometric outcomes of a new cartilage conduction hearing device (CCD) with traditional bone conduction hearing devices (BCDs)....
Clinical trial and crossover study design....
Tertiary academic center....
Sixteen adults (19 ears) with congenital aural atresia or overclosed ear canals who previously underwent BCD implantation were fitted with a CCD. Audiometric data were collected with use of the BCD an...
The mean pretreatment 4-frequency pure tone average was 81 dB. The mean aided pure tone averages with the BCD and CCD were 27 and 32 dB (P = .002), and the mean functional gains were 54 and 49 dB (P =...
Pure tone audiometric outcomes with the BCD show a small advantage over the CCD, with the difference driven mainly by high-frequency responses. Speech outcomes were equivalent apart from the +5-db SNR...
To evaluate speech in noise results and subjective benefit in bilateral active bone conduction implant (ABCI) for bilateral mixed hearing loss....
Prospective, comparative....
Ear, Nose and Throat Unit, Department of Surgical Sciences, University of Turin....
Seven patients with conductive/mixed hearing loss....
Patients underwent simultaneous or sequential bilateral surgery for ABCI....
The speech intelligibility in noise was assessed with the Ita Matrix test in summation, squelch and head shadow settings. First, the tests were performed with one device activated in the ear with lowe...
When bilateral devices were activated, an improvement of signal-to-noise ratio was observed in all settings. The difference between bilateral and unilateral stimulation is 4.66 dB ( p = 0.016) in the ...
In symmetric mixed bilateral hearing loss, rehabilitation with an ABCI fitted bilaterally shows audiologic advantages in speech perception in noise, not only thanks to the summation effect and by redu...
Under bone conduction (BC) stimulation, the otic capsule, and surrounding temporal bone, undergoes a complex 3-dimentional (3D) motion that depends on the frequency, location and coupling of the stimu...
Experiments were conducted in 3 fresh frozen cadaver heads, individually on each temporal bone, resulting in a total of 6 samples. The skull bone was stimulated, via the actuator of a BC hearing aid (...
While there were limited differences in the magnitude of the motion across the skull base, there were major differences in the deformation of different sections of the skull. Specifically, the bone ne...
The area around the otic capsule appears rigid up to significantly higher frequencies than the rest of the skull surface, resulting in primarily inertial loading of the cochlear fluid. Further work sh...
The active transcutaneous bone conduction implant (tBCI; BONEBRIDGE™ BCI 601; MED-EL, Innsbruck, Austria) is fixed to the skull with two self-tapping screws in predrilled screw channels. The aim of th...
Nine patients (mean age 37 ± 16 years, range 14-57 years) were examined pre- and 12 months postoperatively for word recognition scores (WRS) at 65 dB SPL, sound-field (SF) thresholds, bone conduction ...
Due to avoidance of one surgical step, the surgical technique was simplified. Mean WRS in SF was 11.1 ± 22.2% (range 0-55%) pre- and 77.2 ± 19.9% (range 30-95%) postoperatively; mean SF threshold (pur...
Implant fixation by means of self-drilling screws was safe and effective in all nine patients. There was significant audiological benefit 12 months after implantation....
To determine and compare the benefits a novel adhesive bone-conduction system and a conventional bone-conduction hearing aid (BCHA) on a softband for children with conductive hearing loss....
Prospective, single-subject randomized, crossover trial....
Tertiary referral center in Australia....
Eight children aged from 4 to 17 years with conductive hearing loss....
Rehabilitative with participants using the novel adhesive bone-conduction aid and a BCHA....
Aided thresholds, as well as speech perception in quiet, unaided and aided with the novel adhesive bone-conduction aid and BCHA on a softband. For the six older children, speech in noise testing was a...
The mean unaided four frequency average hearing levels was 48 dB HL for air conduction, 10.5 dB HL for bone conduction, with a mean air-bone gap in the aided ear of 37.5 dB HL.Four-frequency average h...
The novel device provided equivalent performance to the BCHA on all measures and can be considered as an alternative device for pediatric patients with conductive hearing loss....
Exact placement of bone conduction implants requires avoidance of critical structures. Existing guidance technologies for intraoperative placement have lacked widespread adoption given accessibility c...
To report the audiometric and surgical outcomes of a series of patients having undergone implantation of a novel transcutaneous bone conduction implant (t-BCI)....
Retrospective case series....
Single academic tertiary referral center....
Adults (≥18 yr) implanted between December 1, 2019, and August 1, 2021, with audiometric data available before and after device implantation and a minimum of 4 weeks follow-up....
Surgical t-BCI....
Change in aided pure tone average (PTA) after implantation. Secondary outcomes include average operative time, and adverse events....
Twenty-three patients underwent implantation of the t-BCI via either a conventional or minimally invasive surgical approach. The most common indication for implantation was unilateral conductive heari...
Forming the largest series of patients implanted with this t-BCI in the published literature, our data demonstrate that implantation of the device is feasible via either a traditional or minimally inv...
When presenting a stereo sound through bilateral stimulation by two bone conduction transducers (BTs), part of the sound at the left side leaks to the right side, and vice versa. The sound transmitted...
To evaluate clinical and audiometric outcomes of adult and pediatric patients implanted with a semi-implantable transcutaneous active bone-conduction implant....
Retrospective chart review....
Two tertiary referral centers....
Subjects implanted with the semi-implantable transcutaneous active bone-conduction implant called BoneBridge....
Implantation of the BoneBridge and audiometric evaluations....
Audiometric, clinical, and surgical outcomes as well as complications....
Forty-two adults and 20 children were implanted for conductive or mixed hearing loss as well as single-sided deafness. Implantation significantly improved mean air-conduction pure-tone average from 72...
In a large retrospective series consisting of both pediatric and adult patients, implantation with a transcutaneous active bone-conduction implant was found to be a reliable aural rehabilitation optio...
Sound transmission to the human inner ear by bone conduction pathway with an implant attached to the otic capsule is a specific case where the cochlear response depends on the direction of the stimula...
